The US Patent and Trademark Office (USPTO) has granted a patent for Sanuwave Health's orthoPACE systemto treat orthopedic conditions.

The patent covers the treatment of orthopedic conditions such as tendinitis, osteoporosis and actual bone stress fracture healing.

The orthoPACE system incorporates the company’s proprietary pulsed acoustic cellular expression (PACE) technology platform, which delivers extracorporeal shock waves to treat chronic and acute conditions in bone and soft tissue.

orthoPACE features a new applicator that may reduce or completely eliminate anesthesia for some patients.

The shock wave spectrum produces tensile stresses on cells and tissue structures to promote angiogenic and positive inflammatory responses, and initiate the healing cascade.

Sanuwave president and CEO Christopher Cashman said the issuance of this patent provides intellectual property protection for PACE technology in a variety of musculoskeletal indications whose combined market potential exceeds $1bn in the US.

"This is important as we begin to execute our regulatory strategy for orthoPACE in the US," Cashman said.